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ABSTRACT 
 
G-protein-coupled receptors (GPCRs) form the largest class of membrane proteins 
and are an important target for therapeutic drugs. These receptors are highly dynamic 
proteins sampling a range of conformational states in order to fulfil their complex 
signalling roles. In order to fully understand GPCR signalling mechanisms it is 
necessary to extract the receptor protein out of the plasma membrane. Historically this 
has universally required detergents which inadvertently strip away the annulus of lipid 
in close association with the receptor and disrupt lateral pressure exerted by the 
bilayer. Detergent-solubilised GPCRs are very unstable which presents a serious 
hurdle to characterisation by biophysical methods. A range of strategies have been 
developed to ameliorate the detrimental effect of removing the receptor from the 
membrane including amphipols and reconstitution into nanodics stabilised by 
membrane scaffolding proteins but they all require exposure to detergent. 
Poly(styrene-co-maleic acid) (SMA) incorporates into membranes and spontaneously 
forms nano-scale SMA lipid particles (SMALPs), effectively acting like a ‘molecular 
pastry cutter’ to ‘solubilise’ GPCRs in the complete absence of detergent at any stage 
and with preservation of the native annular lipid throughout the process. GPCR-
SMALPs have similar pharmacological properties to membrane-bound receptor, 
exhibit enhanced stability compared to detergent-solubilised receptors and being non-
proteinaceous in nature, are fully compatible with downstream biophysical analysis of 
the encapsulated GPCR. 
 
Keywords: SMALP, G-protein-coupled receptor (GPCR), detergent-free, adenosine 
receptor, membrane protein solubilisation, protein thermostability. 
 
Abbreviations: 
 
A2aR, adenosine A2a receptor; A2aR-SMALP, SMALP-solubilised A2aR; A2aR-DDM, 
DDM-solubilised A2aR; 1-AR, 1-adrenergic receptor; 2-AR, 2-adrenergic receptor; 
CD, circular dichroism; DDM, n-dodecyl--D-maltopyranoside; DMPC, 1,2-dimyristoyl-
sn-glycero-3-phosphocholine; GPCR, G-protein-coupled receptor; MAPK, mitogen-
activated protein kinase; MSP, membrane scaffolding protein; SMA, poly(styrene-co-
maleic acid); SMALP, SMA lipid particle; V1aR, V1a vasopressin receptor. 
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Introduction. 
G-protein-coupled receptors (GPCRs) form the largest class of membrane proteins in 
the human genome with >800 unique GPCRs. These receptors regulate a plethora of 
physiological responses which has made them the primary focus for therapeutic 
intervention. Such is the importance of GPCRs to cell signalling and health that 50% 
of all prescribed drugs and 25% of the top-selling drugs generate their effects by 
modulating the function of members of this receptor family [1]. The natural activators 
of GPCRs are very diverse in their physico-chemical characteristics ranging from 
photons and small biogenic amines to peptides and large glycoproteins. Despite this 
pronounced diversity in the nature of the agonists, these receptors share a conserved 
protein architecture comprising a bundle of seven transmembrane (TM) helices linked 
by extracellular loops (ECLs) and intracellular loops (ICLs) [2]. GPCRs have been 
subdivided into families on the basis of sequence conservation [3], with three of these 
families being of particular importance: the rhodopsin/-adrenergic receptor family 
(Family A), the secretin receptor family (Family B) and the metabotropic glutamate 
receptor family (Family C). The largest of these families by far is Family A. 
 
GPCRs are highly dynamic in their conformation.   
It was long-thought that GPCRs were simply on/off switches which existed in two 
conformations, with the ‘on’ conformation being induced by the binding of an agonist. 
The activated receptor then activated a specific G-protein to initiate an intracellular 
signal. In contrast, it was thought that antagonists did not induce this conformational 
change but merely occupied the binding site thereby preventing activation by agonist. 
Subsequently, it was proposed that rather than acting as simple on/off switches, 
GPCRs existed in an equilibrium between the inactive (R) conformation and the active 
(R*) conformation and that agonists and inverse agonists stabilised the conformations 
R* and R, respectively. It is now recognised that GPCR signalling is extremely complex 
and that the receptors can exist in a spectrum of conformational states. Individual 
GPCRs can signal through multiple intracellular cascades by activating more than one 
class of G-protein and can also initiate G-protein-independent signalling such as -
arrestin-dependent GPCR activation of mitogen-activated protein kinase (MAPK) [4]. 
Some agonists activate multiple signalling cascades equally whereas other agonists 
are ‘biased’ in that they selectively activate one signalling pathway over another. 
Furthermore, the pharmacological classification of an individual ligand binding to a 
GPCR can be dictated by the signalling system being assayed. For example, the 
peptide SPG binds to the V1a vasopressin receptor (V1aR) which stimulates MAPK but 
blocks V1aR-mediated inositol phosphate signalling [5]. Full agonists and partial 
agonists possessing different sub-sets of functional groups stabilise different receptor 
conformations [6, 7] and establish different networks of hydrogen bonds in the binding 
site [8]. Consequently, instead of possessing just one R* conformation, activated 
GPCRs can sample a wide spectrum of distinct active receptor conformations (R*, 
R*’,R*’’ etc.), with different efficacies for different signalling systems. The precise 
receptor conformation stabilised by a particular ligand will dictate that ligand’s 
pharmacological profile. A completely new level of conformational complexity is 
presented by allosteric ligands, which bind to sites which are discrete to the classical 
(orthosteric) binding site. Allosteric ligands alter the receptor conformation upon 
binding thereby tuning the GPCR signalling up or down [9]. From what has been said 
above, it can be appreciated that the normal functioning of a GPCR requires the 
receptor protein to populate a wide range of conformational states. Defining these 
multifarious conformational states and characterising the transition between states is 
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a pre-requisite to fully understanding GPCR signalling. Such experiments usually 
require purified GPCR. However, the flexible and highly dynamic nature inherent in 
the receptor protein presents a serious obstacle to such studies.   
 
Studying isolated GPCRs – some problems. 
In common with integral membrane proteins in general, GPCRs have evolved to exist 
embedded in a lipid bilayer. This requires the protein to stably interact with two discrete 
physico-chemical environments simultaneously; i) the aqueous phase plus charged 
lipid headgroups of the membrane and ii) the hydrophobic membrane interior. Both of 
these environments contribute to the overall functional protein fold of the receptor. 
When GPCRs are studied in situ this is not a problem, but it becomes a problem when 
experiments require the receptor to be extracted from the complex environment of the 
plasma membrane. This has universally required the use of a class of surfactants 
commonly referred to as detergents. Although detergents are very good at molecular 
dispersal and in gross terms the detergent micelles approximate to the physico-
chemical properties of a membrane, micelles are actually poor mimics of the plasma 
membrane bilayer. The solubilisation process strips away the annular lipid in close 
association with the protein and it is thought that this removal of lipid from membrane 
proteins may be the most common cause of solubilisation-induced loss of function 
[10]. The lipid components of native cell membranes are very heterogeneous with 
respect to structure, head group and acyl chains and membrane proteins can have a 
specific requirement for a particular lipid. It is well-established that GPCRs can be 
affected by the nature of juxtaposed lipid. Cholesterol can modulate receptor 
conformation [11] and function [12, 13]. Indeed a specific cholesterol binding site 
incorporating a ‘cholesterol consensus motif’ has been proposed for some GPCRs 
following the identification of cholesterol in GPCR crystal structures [14]. Very recently, 
it has been shown that phospholipids can act as allosteric regulators of GPCRs with 
phosphatidylglycerol and phosphatidylethanolamine favouring active and inactive 
conformational states of the 2-AR respectively [15]. Disruption of the lipid bilayer by 
detergent not only removes these structural nuances, it also removes the lateral 
pressure exerted by the bilayer structure on the embedded membrane proteins. This 
lateral pressure has been shown to be important for maintaining the native fold and 
activity of membrane proteins [16, 17]. It would be expected that removal of lateral 
pressure would be particularly disruptive to integral membrane proteins that are 
conformationally dynamic, such as GPCRs. Consequently, detergent solubilisation of 
membrane proteins typically results in protein instability and progressive loss of 
function. Continued presence of detergent is required to prevent aggregation of 
detergent-solubilised protein despite the detrimental stability implications cited above. 
These problems are reflected in the relatively very small number of high-resolution 
crystal structures for membrane proteins compared to soluble proteins. 
 
Strategies for studying isolated GPCRs.  
A significant advance was made by the development of a new detergent which was 
less perturbing to GPCR conformation [18] but receptor stability remained an issue. 
One approach to increasing the stability of GPCRs in detergent is to alter the receptor 
sequence to generate a modified protein with significantly greater tolerance to 
detergent exposure. This has been achieved by two different methodologies: i) a 
programme of extensive mutagenesis was used to develop a series of specific point 
mutations that generated a stabilised receptor (referred to as a StaR) in a specific 
conformation [19] and ii) a directed evolution method was developed using E.coli that 
5 
 
allowed the direct selection of GPCRs stable in a pre-selected detergent from libraries 
containing >100 million variants [20]. As an alternative strategy, the solubilising 
detergent used initially to extract the receptor has been replaced with amphipathic 
polymers (amphipols) [21] or by a stabilising engineered -sheet peptide [22]. Sligar 
and collaborators have developed protocols for encapsulating detergent-solubilised 
GPCRs in a lipid disc stabilised by an annulus of membrane scaffolding proteins 
(MSPs) derived from apolipoproteins, thereby replacing the detergent micelle with a 
phospholipid bilayer [23]. 
 
Detergent-free extraction of GPCRs within a nano-scale native lipid bilayer. 
Historically there has been an absolute requirement for detergent to solubilise GPCRs 
despite the problems this causes. In an ideal situation, the ‘solubilisation’ would 
remove the GPCR from the membrane still embedded in a nanoscale section of the 
native bilayer, thereby preserving the closely-associated annular lipid and lateral 
pressure. This is now possible using poly(styrene-co-maleic acid) (SMA) (Figure 1) 
which incorporates into membranes and spontaneously forms nano-scale SMA lipid 
particles (SMALPs), effectively acting like a ‘molecular pastry cutter’. In 2009, SMA 
polymer with a 2:1 ratio of styrene to maleic acid was shown to solubilise membrane 
proteins [24]. Biophysical analysis of SMALPs revealed that the SMA polymer forms 
an annulus surrounding and stabilising a disc of lipid bilayer (~10 nm diameter), 
possessing the expected thickness of a cell membrane, with the styrene rings of the 
polymer intercalated between the lipid acyl chains and the maleic acid likely to interact 
with the lipid headgroups  [25]. The behaviour of lipids in a 2:1 SMA polymer SMALP 
was bilayer-like, as the transition temperature for gel to liquid phase transition of 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) was only 1 C lower in the SMALP. 
A 3:1 SMA polymer has also been used to solubilise proteins including the 
Halobacteria proton pump bacteriorhodopsin [26]. However, the DMPC transition 
temperature in a 3:1 SMA polymer SMALP was considerably reduced (~10 C) 
indicating a perturbation of the lipid bilayer. This could be important as membrane 
fluidity could impact on the conformational flexibility of dynamic proteins like GPCRs. 
We used 2:1 SMA polymer to solubilise the adenosine A2a receptor (A2aR) and purify 
it to homogeneity [27]. A2aR-expressing membranes of the yeast Pichia pastoris, at a 
final concentration of 40 mg/ml (wet weight) were incubated with SMA (2.5 % w/v final 
concentration) for 2 h at 25 C with gentle stirring. Non-solubilized material was 
sedimented at 100,000 x g for 1 h at 4 C, to yield a supernatant containing A2aR-
SMALP [27]. This was the first time that a GPCR had been solubilised and purified in 
the total absence of detergent at any stage. The efficiency of extraction of active A2aR 
expressed in HEK 293T cells using our SMALP approach was directly compared to 
that of n-dodecyl-ß-D-maltoside (DDM), a detergent commonly employed to solubilise 
GPCRs. The total binding of the A2aR-SMALP was 2.0 ± 0.24 pmol/mg of protein (n=3) 
equivalent to a yield of 23.3 ± 2.7 % compared to the original HEK 293T cell membrane 
preparation. This was similar to the recovery seen from detergent (DDM) solubilisation 
of A2aR (27.6 ± 11.4 %, n=3). However, it was noted that the recovery with A2aR-
SMALP was less variable than the A2aR-DDM [27]. It has been our experience that the 
extraction of GPCR-SMALPs is equally effective from a range of commonly employed 
GPCR expression systems, including yeast (P. pastoris, mammalian cells (HEK293T 
and COS-7 cells) and insect cells (Sf9 cells).  Given that the A2aR encapsulated in the 
SMALP had been embedded in native membrane (Figure 2) throughout the 
solubilisation process, we hypothesised that it would display increased stability 
compared to detergent-solubilsed A2aR. We made a direct comparison between the 
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thermostability of A2aR solubilised by DDM and A2aR-SMALP, using radioligand 
binding assays with [3H]ZM241385 to monitor preservation of receptor conformational 
integrity. We established that the A2aR-SMALP displayed increased thermostability 
over A2aR-DDM to a range of challenges including storage at 37 C and storage at 4 
C. Repeated freeze-thaw cycles are particularly damaging to detergent-solubilised 
GPCRs. A2aR-DDM lost all binding capability after just one freeze-thaw whereas the 
A2aR-SMALP binding capability was undiminished after 5 freeze-thaw cycles [27]. 
Such is the stability of the A2aR-SMALP that it could be freeze-dried onto a tube and 
when re-hydrated with buffer retained ~70% of its binding capability. The improved 
stability of the GPCR was independent of the source of receptor as this phenomenon 
was observed with A2aR-SMALP generated from either the yeast P. pastoris or 
mammalian HEK 293T cells. The lipid composition of yeast and mammalian cells differ 
particularly with respect to cholesterol which is replaced by ergosterol in yeast [28] but 
the thermostabilty endowed by the SMALP on A2aR was comparable  between the two 
expression systems. 
 
GPCR-SMALP facilitates biophysical analysis. 
A great strength of the GPCR-SMALP is that the co-polymer stabilising the 
nanoparticle is non-proteinaceous in nature. Consequently it does not interfere with 
analysis of the encapsulated GPCR protein using biophysical methods such as CD 
[27]. The GPCR-SMALP would also facilitate the use of spectroscopic analysis of 
GPCR conformational changes using endogenous tryptophan fluorescence or 
introduced fluorescent moieties such as IAEDANS or bimane. The SMALP particles 
may however be too large for NMR currently. In contrast, a range of biophysical 
methods cannot be easily applied to GPCRs embedded in MSP-nanodiscs, as the 
discs effectively have an inherent contaminant in the form of the stabilising scaffolding 
protein which can interfere with studies on the reconstituted GPCR protein. 
 
Conclusion and future perspectives. 
A range of self-assembly systems has been developed which can be applied to 
studying and purifying GPCRs, including bicelles, amphipols, MSP-stabilised 
nanodiscs and SMALPs [29] but only the approach exploiting SMALPs is totally 
detergent-free, retains lateral pressure and preserves the native annular lipid 
environment of the receptor throughout. It is anticipated that GPCR-SMALPs will 
facilitate our understanding of fundamental GPCR molecular mechanisms using 
biophysical techniques. GPCR-SMALPs may also have general utility in a range of 
receptor-based assays linked to drug discovery. 
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FIGURE LEGENDS 
 
Figure 1  Poly(styrene-co-maleic acid). 
 
Figure 2 An A2aR-SMALP. 
A schematic representation of an A2aR-SMALP viewed from within the 
plane of the membrane. Only the receptor (coloured) and lipid molecules 
(grey) are shown. 
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